Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Metastatic Urothelial Cancer × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 89 Carcinoma, Non-Small-Cell Lung 79 Prostatic Neoplasms 72 Multiple Myeloma 57 Leukemia, Myeloid, Acute 54 Neoplasms 50 Colorectal Neoplasms 44 Lung Neoplasms 41 Neoplasm Metastasis 35 Squamous Cell Carcinoma of Head and Neck 33 Ovarian Neoplasms 32 Melanoma 32 Lymphoma 32 Brain Neoplasms 32 Triple Negative Breast Neoplasms 29 Pancreatic Neoplasms 29 Recurrence 27 Carcinoma, Renal Cell 26 Urinary Bladder Neoplasms 23 Carcinoma, Hepatocellular 23 Sarcoma 22 Leukemia, Lymphocytic, Chronic, B-Cell 22 Glioblastoma 22 Stomach Neoplasms 20 Lymphoma, Large B-Cell, Diffuse 20 Lymphoma, Follicular 20 Glioma 19 Uterine Cervical Neoplasms 18 Precursor Cell Lymphoblastic Leukemia-Lymphoma 18 Lymphoma, Non-Hodgkin 18

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1 enfortumab vedotin 1 avelumab 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡